AIM: To explore the role of radio-frequency ablation (RFA) as a treatment for hilar cholangiocarcinoma. METHODS: Eleven patients with obstructive cholestasis underwent Computed Tomography (CT) examination, occupying lesions were observed in the hepatic hilar region in each patient. All lesions were confirmed as cholangioadenocarcinoma by biopsy and were classified as type III or IV by percutaneous transhepatic cholangiography. Patients were treated with multiple electrodes RFA combined with other adjuvant therapy. The survival rate, change of CT attenuation coefficient of the tumor and tumor size were studied in these patients after RFA. RESULTS: In a follow-up CT scan one month after RFA, a size reduction of about 30% was observed in six masses, and two masses were reduced by about 20% in size, three of the eleven masses remained unchanged. In a follow-up CT scan 6 mo after RFA, all the masses were reduced in size (overall 35%), in which the most significant size reduction was 60%. The survival follow-up among these eleven cases was 18 mo in average. Ongoing follow-up showed that the longest survival case was 30 mo and the shortest case was 10 mo. CONCLUSION: RFA is a microinvasive and effective treatment for hilar cholangiocarcinoma.
AIM: To explore the role of radio-frequency ablation (RFA) as a treatment for hilar cholangiocarcinoma. METHODS: Eleven patients with obstructive cholestasis underwent Computed Tomography (CT) examination, occupying lesions were observed in the hepatic hilar region in each patient. All lesions were confirmed as cholangioadenocarcinoma by biopsy and were classified as type III or IV by percutaneous transhepatic cholangiography. Patients were treated with multiple electrodes RFA combined with other adjuvant therapy. The survival rate, change of CT attenuation coefficient of the tumor and tumor size were studied in these patients after RFA. RESULTS: In a follow-up CT scan one month after RFA, a size reduction of about 30% was observed in six masses, and two masses were reduced by about 20% in size, three of the eleven masses remained unchanged. In a follow-up CT scan 6 mo after RFA, all the masses were reduced in size (overall 35%), in which the most significant size reduction was 60%. The survival follow-up among these eleven cases was 18 mo in average. Ongoing follow-up showed that the longest survival case was 30 mo and the shortest case was 10 mo. CONCLUSION: RFA is a microinvasive and effective treatment for hilar cholangiocarcinoma.
Authors: R Robles; P Parrilla; F S Bueno; P Ramírez; J A Luján; J M Rodríguez; F Acosta; J López; Q Hernández Journal: Transplant Proc Date: 1999-09 Impact factor: 1.066
Authors: F Berr; A Tannapfel; P Lamesch; S Pahernik; M Wiedmann; U Halm; A E Goetz; J Mössner; J Hauss Journal: J Hepatol Date: 2000-02 Impact factor: 25.083
Authors: B Launois; J Terblanche; M Lakehal; J M Catheline; E Bardaxoglou; S Landen; J P Campion; F Sutherland; B Meunier Journal: Ann Surg Date: 1999-08 Impact factor: 12.969
Authors: P Born; T Rösch; K Brühl; W Sandschin; N Weigert; R Ott; E Frimberger; H D Allescher; W Hoffmann; H Neuhaus; M Classen Journal: Z Gastroenterol Date: 2000-06 Impact factor: 2.000
Authors: Bo La Yun; Jeong Min Lee; Ji Hyun Baek; Se Hyung Kim; Jae Young Lee; Joon Koo Han; Byung Ihn Choi Journal: Korean J Radiol Date: 2011-08-24 Impact factor: 3.500